Neuroscientific Biopharmaceuticals Ltd. · ASX:NSB
Neuroscientific Biopharmaceuticals — Shareholder Meeting (November 2023)
16 slides from Neuroscientific Biopharmaceuticals's shareholder meeting presentation, Nov 30, 2023
Slide 1: Chairman's 2023 Annual General Meeting Address
ASX ANNOUNCEMENT 30 NOVEMBER 2023 Chairman’s 2023 Annual General Meeting Address Good afternoon ladies and gentlemen. Welcome to the 2023 AGM for NeuroScientific Biopharmaceuticals Limited. My name is Paul Rennie, the Chairman of NeuroScientific. I will also Chair today’s meeting. Thank you for taki
Slide 2: About NeuroScientific Biopharmaceuticals Ltd
About NeuroScientific Biopharmaceuticals Ltd NeuroScientific Biopharmaceuticals Limited (ASX: NSB) is a company developing peptide-based pharmaceutical drugs that target a number of neurodegenerative conditions with high unmet medical demand. The company’s product portfolio includes EmtinBTM, a ther
Slide 3: Novel Drug Therapies for Neurodegenerative Conditions
For personal use only NOVEL DRUG THERAPIES FOR NEURODEGENERATIVE CONDITIONS Annual General Meeting 30 NOVEMBER 2023 • ASX: NSB neuroscientific.com
Slide 4: Disclaimer
DISCLAIMER The purpose of the presentation is to provide an update of the business of NeuroScientific Biopharmaceuticals Ltd For personal use only (“NeuroScientific”, or “the Company”). These slides have been prepared as a presentation aid only and the information they contain may require further ex
Slide 5: Board and Management
For personal use only BOARD AND MANAGEMENT Paul Rennie Dr Anton Uvarov Stephen Quantrill Chairman and Interim CEO Non-Executive Director Non-Executive Director • Founder of Paradigm (ASX: PAR) • Founding Director of Actinogen • 20+ years corporate advisory • Former COO of Mesoblast (ASX: (ASX: ACW)
Slide 6: Financial Metrics and Milestones
FINANCIAL METRICS AND MILESTONES FINANCIALS CAPITAL STRUCTURE For personal use only ▪ ~$4M cash on hand ASX code NSB ▪ R&D Tax refund due Shares on issue 143M ▪ Sufficient cash to develop lead project to clinical trials. Price $0.07 TARGET MILESTONES* Market cap $10.01M ▪ Q1 2024 – Lodge Pre-IND mee
Slide 7: Company Highlights 2022-2023
COMPANY HIGHLIGHTS 2022-2023 ▪ Sept 2022 For personal use only • HREC decision to not approve Phase 1 trial • CEO Resigns ▪ Nov 2022 • Paul Rennie takes over CEO role whilst an international search was started for a new CEO • NSB focuses all its efforts on overcoming the deficiencies identified by t
Slide 8: Company Highlights 2022-2023 (con't)
COMPANY HIGHLIGHTS 2022-2023 (con’t) NSB continues to review new licensing opportunities For personal use only ▪ Dec 2022 • New Patent application lodged ▪ Mar 2023 • NSB commences Phase 0 Study Investigating Exploratory Immune Cell Response of EmtinBTM following Ex Vivo Stimulation of Human Blood ▪
Slide 9: EmtinB: Proven Activity In The Laboratory
EMTINBTM Proven Activity In The Laboratory For personal use only STIMULATES CELL PROMOTES AXONAL REGULATES PROMOTES SURVIVAL PATHWAYS REGENERATION INFLAMMATION REMYELINATION Activates cell survival Activation of LRP-1 also Downregulates Stimulates proliferation and pathways by specifically promotes
Slide 10: Comparison of Systemic and Ophthalmology programs
Comparison of Systemic and Ophthalmology programs Systemic treatment Description Ophthalmology (Multiple Sclerosis) Safety Safe Safe For personal use only Data supports efficacy, though Data supports efficacy. Efficacy uncertainty still exists as to whether Confirmed ability to reach target sites. w
Slide 11: EmtinB promotes survival of retinal ganglion cells and protects the optic nerve
EMTINBTM promotes survival of retinal ganglion cells and protects the optic nerve For personal use only ▪ We evaluated where EmtinB™ was distributed in the eye. The study OPTIC NERVE RETINAL TISSUE confirmed that EmtinB™ was distributed through-out the eye and was seen in the optic nerve and nerve h
Slide 12: EmtinB Ocular Data
EMTINB™ OCULAR DATA Neuroprotection and regeneration of the optic nerve GLAUCOMA PIG MODEL For personal use only ▪ EmtinBTM demonstrated neuroprotection in glaucoma IOP pig model ▪ High intraocular pressure pig model is the closest experiment to replicate severe human glaucoma pathology; positive re
Slide 13: Glaucoma Opportunity
GLAUCOMA OPPORTUNITY ▪ Glaucoma is the leading cause of irreversible blindness in Australia For personal use only ▪ Glaucoma is rapidly increasing in prevalence due to an aging population. ▪ The global prevalence of glaucoma reached 80 million in 2020 with six million of these patients bilaterally b
Slide 14: Commercialisation Strategy
COMMERCIALISATION STRATEGY For personal use only The Company’s commercialisation strategy involves developing its drug candidates through to successful completion of Phase II clinical studies and then license them to a pharmaceutical or biotechnology company for further clinical development / market
Slide 15: Summary
SUMMARY ▪ The Company has conducted an EmtinB™ project review & confirms EmtinB™ as highly prospective as NSB’s lead For personal use only project. ▪ EmtinBTM is an exciting lead project with significant therapeutic potential. ▪ EmtinBTM for the treatment of neurodegenerative diseases of the eye has
Slide 16: For more information please contact
For personal use only neuroscientific.com For more information please contact: Stephen Carter Chief Executive Officer [email protected]
NeuroScientific Biopharmaceuticals — Shareholder Meeting (November 2023) on 6ix